The US Food and Drug Administration’s (FDA) decision to allow 20 ZYN nicotine pouch products to carry a specific reduced-risk claim has created a striking contrast with the direction of European Union policy, as Brussels prepares new product rules and proposes EU-wide taxation of nicotine pouches.
The United States Food and Drug Administration has authorised 20 ZYN nicotine pouch products to be marketed with a statement informing adult smokers that completely replacing cigarettes with the pouches can reduce the risk of several serious diseases.
The decision, issued on 30 June 2026, represents the first time that the FDA has granted Modified Risk Tobacco Product orders to nicotine pouches.
The authorised wording states:
“Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”
The orders cover ten varieties of ZYN, each sold in nicotine strengths of 3mg and 6mg. The products include Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint and Wintergreen.
The manufacturer, Swedish Match USA, is owned by Philip Morris International. The products had already received FDA authorisation to remain on the US market in January 2025, but the new decision goes considerably further by permitting a specific comparative health claim.
The FDA said its decision followed an extensive scientific review and was intended to give adult tobacco users accurate information about differences in risk between products.
“FDA’s review of modified risk products is intended to ensure that adult users have clear, science-based information about the relative harms of tobacco products, so they can make informed choices,” said Bret Koplow, acting director of the FDA’s Centre for Tobacco Products.
The ruling does not mean that ZYN is harmless, nor does it approve the products as medicines or smoking-cessation treatments. Nicotine is addictive, and the FDA continues to advise people who do not currently use tobacco or nicotine not to begin.
The significance of the decision lies instead in the regulator’s formal recognition that nicotine products can present very different levels of risk.
Switching, rather than dual use
A crucial qualification is contained in the phrase “instead of cigarettes”. The authorised claim applies to smokers who replace cigarettes with ZYN. It does not promise the same reduction in risk to consumers who use nicotine pouches while continuing to smoke.
Cigarettes burn tobacco, creating smoke containing toxic substances responsible for most smoking-related cancers, cardiovascular disease and respiratory illness. Nicotine pouches deliver nicotine through the lining of the mouth without burning tobacco or producing smoke.
This difference is central to the principle of tobacco harm reduction: smokers who cannot or do not wish to stop using nicotine may nevertheless reduce their health risks by moving away from combustible products.
The FDA’s decision therefore recognises an important distinction that is frequently blurred in political debate. A product can be addictive and unsuitable for non-users while still being substantially less dangerous than smoking.
UK-based public health commentator Clive Bates, a former director of Action on Smoking and Health, has argued that nicotine pouches could deliver benefits comparable to those associated with the use of Swedish snus in Scandinavia.
“Tobacco-free nicotine pouches with a consumer acceptable nicotine content have the potential to benefit public health in the same way that is documented for Swedish snus in Scandinavia, that is, by serving as a low-risk alternative to cigarettes”, Bates said.
“The European Commission should pay close attention to FDA’s exhaustive process and extensive reasoning. It’s unusual to have anything good to say about the Federal government these days, but this is an important exception, where the right answer has been reached for the right reasons”, he added.
Bates has also argued that poorly designed regulation, including excessively low nicotine limits, could make pouches less effective as substitutes for cigarettes and unintentionally protect the market for combustible tobacco.
Why the FDA decision matters for Europe
The American ruling comes at a particularly important moment for the European Union.
The European Commission is simultaneously advancing a formal proposal to overhaul tobacco taxation (TED) and preparing a broader revision of the EU legislation governing tobacco and nicotine products, their presentation, sale, advertising and promotion.
Nicotine pouches are not comprehensively regulated at EU level under the current Tobacco Products Directive (TPD). Because they contain nicotine but no tobacco, they fall outside many of the harmonised provisions that apply to cigarettes, roll-your-own tobacco, heated tobacco and electronic cigarettes. The result is a fragmented European market.
Some member states permit nicotine pouches subject to national restrictions. Others have introduced nicotine limits, packaging and warning requirements or advertising controls, while France has pursued a prohibition.
Different national rules create uncertainty for consumers and manufacturers and complicate enforcement across the EU’s internal market.
The Commission’s April 2026 evaluation of the European tobacco-control framework identified the rapid growth of nicotine pouches, electronic cigarettes and heated tobacco products as one of the main challenges that existing EU legislation is no longer adequately equipped to address.
The evaluation concluded that EU rules had contributed to falling smoking rates and smoking-related deaths but were failing to keep pace with changes in products, marketing practices and consumer behaviour.
The EC is particularly concerned about the use of novel nicotine products among children, adolescents and young adults. However, the FDA decision introduces an additional issue that EU policymakers will now find difficult to avoid: whether new EU rules should recognise differences in risk between combustible cigarettes and smoke-free nicotine products.
Two contrasting regulatory philosophies
The emerging difference between Washington and Brussels is not simply that one jurisdiction is permissive and the other restrictive.
The FDA subjects nicotine products to an exceptionally demanding premarket review. Products must receive authorisation before they can legally be marketed, and separate evidence is required before a manufacturer may make a modified-risk claim.
The FDA can impose marketing conditions, require post-market surveillance and withdraw an order if later evidence shows that the product no longer benefits public health.
Its approach nevertheless accepts that consumers should be told when credible evidence shows that completely switching from one product to another reduces disease risk.
The Commission’s current approach places greater emphasis on reducing the overall attractiveness and consumption of tobacco-related and nicotine products. Its taxation proposal explicitly presents nicotine pouches as products that can prolong addiction or act as substitutes for cigarettes, especially among young people.
These positions are not necessarily irreconcilable.
The EU could impose age controls, marketing restrictions, ingredient standards and proportionate nicotine limits while still recognising that adult smokers may benefit from switching completely away from cigarettes.
It could also prohibit unsubstantiated commercial claims while creating an evidence-based process through which manufacturers could apply for permission to communicate verified differences in risk.
The alternative would be to impose increasingly similar taxation, warnings and advertising rules on products with significantly different health consequences.
A test for evidence-based policymaking
The EC ran a public consultation on revisions to both the Tobacco Products Directive (TPD) and the Tobacco Advertising Directive (TAD) from 22 May to 14 August this year. The consultation, is intended to inform a revision of the legislative framework planned before the end of 2026.
It creates an opportunity to consider evidence that was not available when the current Tobacco Products Directive was adopted in 2014.
Nicotine pouches were then a marginal product. They now represent a rapidly expanding category, and national governments are adopting increasingly divergent responses.
The FDA decision does not compel Europe to follow the US model. The EU has different legal structures, public-health priorities and attitudes towards commercial nicotine.
It does, however, establish a significant regulatory precedent.
One of the world’s most influential public-health authorities has concluded that there is sufficient evidence to tell adult smokers that completely switching to specified nicotine pouches reduces their risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis.
That finding sits uneasily with any policy or public communication suggesting that cigarettes and smoke-free nicotine products are essentially equivalent.
The issue is particularly relevant to the Commission’s tax proposal. Taxation affects consumer behaviour partly by changing the relative prices of products. If pouches are taxed so heavily that the economic advantage over cigarettes is substantially reduced, smokers may have less incentive to switch.
Conversely, setting taxes too low could increase affordability and use among young people who have never smoked.
The task for EU legislators is therefore not simply to choose between regulation and deregulation. It is to develop a framework that calibrates restrictions, taxation and consumer information according to evidence about risk, behaviour and population-level effects.
Europe’s choice
While Washington is recognising that adults deserve accurate information about lower-risk alternatives, Brussels is looking for ways to restrict, tax or ban them.
Meanwhile, the EU is failing to control illegal disposable vapes, banned flavours, excessive nicotine levels and unauthorised devices moving through black-market channels. Regulated products are demonised, while illegal and unregulated products keep reaching consumers, including young people.
The forthcoming EU debate will test whether Brussels can reconcile its tobacco-free objective with the potential role of lower-risk alternatives.
The FDA decision makes three points that are likely to shape that discussion.
First, nicotine pouches are not harmless and should not be promoted to children or people who do not use nicotine.
Second, the absence of combustion means that their risks can differ substantially from those associated with cigarettes.
Third, the greatest potential benefit arises when smokers switch completely rather than using pouches alongside continued smoking.
The Commission is right to address gaps in the existing legislation and fragmentation between member states. Common product standards, youth protections and enforcement rules may be necessary for the Single Market to function properly.
But regulation that fails to acknowledge relative risk could also have unintended consequences.
Clive Bates and other harm-reduction advocates argue that treating all nicotine products as though they are similarly dangerous can preserve smoking by discouraging consumers from moving to safer alternatives. European health campaigners respond that the growth of commercially marketed nicotine products could create a new generation of dependent users.
The revised Tobacco Products Directive (TPD) will need to address both concerns.
As the EC completes its consultation and develops its legislative proposal, the American decision gives European policymakers a concrete case study rather than a theoretical argument.
The question is no longer whether a regulator could authorise a carefully limited reduced-risk claim for a nicotine pouch. The FDA has now done so.
The question for Europe is whether its forthcoming legislation will allow comparable scientific evidence to influence regulation, taxation and communication — or whether nicotine pouches will be treated principally as another product to be restricted, irrespective of their potential role in moving smokers away from cigarettes.
Login
